Phase II study of medroxyprogesterone acetate with tamoxifen in advanced renal cell cancer.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D013629:Tamoxifen / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors
D013629:Tamoxifen; D008525:Medroxyprogesterone